North China Pharmaceutical Co Ltd
SSE:600812
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
4.8089
7.01
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
North China Pharmaceutical Co Ltd
Revenue
North China Pharmaceutical Co Ltd
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
N
|
North China Pharmaceutical Co Ltd
SSE:600812
|
Revenue
ÂĄ9.8B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
3%
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Revenue
ÂĄ13.2B
|
CAGR 3-Years
10%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Revenue
ÂĄ9.8B
|
CAGR 3-Years
5%
|
CAGR 5-Years
9%
|
CAGR 10-Years
19%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Revenue
ÂĄ31B
|
CAGR 3-Years
13%
|
CAGR 5-Years
4%
|
CAGR 10-Years
13%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Revenue
ÂĄ40.8B
|
CAGR 3-Years
5%
|
CAGR 5-Years
5%
|
CAGR 10-Years
7%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Revenue
ÂĄ5.8B
|
CAGR 3-Years
94%
|
CAGR 5-Years
37%
|
CAGR 10-Years
N/A
|
|
North China Pharmaceutical Co Ltd
Glance View
In the heart of China's industrial evolution, North China Pharmaceutical Co., Ltd. (NCPC) has thrived as a prominent player in the global pharmaceutical arena. Established in 1953, NCPC has grown from being a state-owned entity to one of the world's largest antibiotic producers. Nestled within the bustling Shijiazhuang region, the company commands a significant presence in the industry, leveraging its extensive experience and formidable R&D capabilities. The backbone of NCPC's operations lies in its integrated production lines, which link raw materials seamlessly with advanced pharmaceutical synthesis processes. This setup enables the company to efficiently churn out a diverse range of products, from bulk antibiotics like penicillin and streptomycin to high-value biotech and nutritional products. NCPC sustains its financial health through a blend of domestic dominance and robust international outreach, catering to over 100 countries. Its revenue streams are diversified across various segments, including prescription drugs, over-the-counter medication, and nutritional supplements. Central to its business model is the balance between cost-effective mass production and a push towards innovation-driven therapies, aligning with China's broader healthcare reforms. The company's growth is further bolstered by strategic partnerships and continuous improvements in its technological framework, ensuring NCPC remains a key contender in the ever-competitive pharmaceutical landscape. Through these strategies, North China Pharmaceutical not only upholds its legacy but continues to write new chapters in the global pharmaceutical story.
See Also
What is North China Pharmaceutical Co Ltd's Revenue?
Revenue
9.8B
CNY
Based on the financial report for Sep 30, 2025, North China Pharmaceutical Co Ltd's Revenue amounts to 9.8B CNY.
What is North China Pharmaceutical Co Ltd's Revenue growth rate?
Revenue CAGR 10Y
3%
Over the last year, the Revenue growth was 1%. The average annual Revenue growth rates for North China Pharmaceutical Co Ltd have been -1% over the past three years , -4% over the past five years , and 3% over the past ten years .